This study is designed to observe the safety and blood concentrations of PF-04995274 during and following the administration of multiple doses of PF-04995274 for a duration of 14 days, in healthy adult and healthy elderly.
To examine the safety and pharmacokinetics of PF-04995274 in healthy adult and healthy elderly subjects after multiple doses.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Masking
DOUBLE
Enrollment
60
0.1 mg PF-04995274, qd, for 14 days or placebo
1 mg PF-04995274, qd, for 14 days or placebo
10 mg PF-04995274, qd, for 14 days or placebo
Pfizer Investigational Site
Overland Park, Kansas, United States
Pfizer Investigational Site
Overland Park, Kansas, United States
Safety Endpoints (Adverse events, Change from baseline in vital signs, Change from baseline in triplicate ECGs, Clinical safety laboratory, Clinical examinations, Digit Symbol Substitution Test (DSST))
Time frame: Day 0 to Day 28
Pharmacokinetic endpoints Plasma concentration of PF 04995274 over time (eg, AUC, Cmax, Tmax, t1/2), Plasma concentration of PF 05082547 over time (eg, AUC, Cmax, Tmax, t1/2).
Time frame: Day 0 to Day 28
Pharmacodynamic endpoint Aldosterone concentration in healthy adult subjects.
Time frame: Day 0 to Day 14
No secondary outcomes
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
15 mg PF-04995274, qd, for 14 days or placebo
1.0 mg PF-04995274, qd, for 14 days or placebo
15 mg PF-04995274, qd, for 14 days or placebo